Enveric Biosciences Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.99. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | XDTE | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $17.40 | $44.76 |
52-Week Low | $1.28 | $36.00 |
Enterprise Value | $408.82K | — |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
No Aura AI signal available yet.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →